PFIZER INC. DL-_05
Commented by Nico Popp on July 29th, 2025 | 07:20 CEST
Study reveals AI catch-up gap among pharmaceutical giants: Opportunities for Roche, Pfizer, and NetraMark?
Many observers believe that AI will revolutionize the biotech and pharmaceutical industries. A study by market researchers at Coherent Solutions now reveals the full picture: the market for biotechnology AI is projected to grow from USD 2.6 billion today to USD 12.8 billion by 2035. This corresponds to an annual growth rate of 18.8%. The report also shows how the industry's major players are preparing for the change. Since the "AI Readiness Index" calculated by the analysts paints a very complex picture, the opportunities for specialized AI investments are significant. We take a closer look at the Coherent Solutions study and introduce a business model poised to revolutionize pharmaceutical research and offer opportunities for investors.
Read
Commented by André Will-Laudien on July 14th, 2025 | 07:25 CEST
DAX correction! Biotech in takeover mode! BioNTech, CureVac, Pfizer, Vidac Pharma, and Kraft Heinz in focus
The stock markets are in top form: both the DAX and the NASDAQ 100 have flexed their muscles in recent days. Prices are being driven primarily by the continued strength of technology stocks and growing hopes for stable global economic growth, despite Donald Trump's tariff madness. At the same time, a growing takeover fever in the biotechnology sector is providing additional momentum. In the field of cancer research in particular, companies such as BioNTech, Moderna, and other specialized mRNA players such as CureVac are increasingly becoming the focus of strategic investors. The fight against cancer is increasingly becoming one of the key drivers for new partnerships and market consolidation. Speculation about possible mergers and billion-dollar acquisitions is currently on the rise again. This opens up an exciting environment for investors, offering opportunities for above-average returns. We identify the trigger points.
Read
Commented by Armin Schulz on July 10th, 2025 | 07:15 CEST
How BioNTech, PanGenomic Health, and Pfizer are using artificial intelligence to cut costs and boost returns
Digitalization is revolutionizing the biotechnology and pharmaceutical industries. Artificial intelligence sifts through billions of pieces of medical data in real time, accelerating drug development by years. This is also demonstrated by the new alliance between Moderna and Google Cloud, which are jointly developing an AI platform for customized mRNA cancer therapies. These technologies reduce production costs by up to 40% and generate disruptive return opportunities. At the same time, personalized medicine is opening up billion-dollar markets. Three companies are turning to artificial intelligence to boost their returns: BioNTech, PanGenomic Health, and Pfizer.
Read
Commented by Armin Schulz on June 24th, 2025 | 07:30 CEST
Portfolio Doubler with Artificial Intelligence: Novo Nordisk, PanGenomic Health, and Pfizer Ignite the Profit Growth in 2025
According to BlackRock Health Sciences, the global healthcare sector is poised for an unprecedented boom in 2025. After years of volatility driven by the pandemic, the industry is now expected to achieve its highest profit growth in almost two decades - and across the board, not just among pandemic-driven outliers. Digital revolutions such as AI-assisted drug development and telemedicine are accelerating change and creating radically new business models. Those who understand the architects of this transformation will recognize the growth drivers of tomorrow. With this in mind, we take a closer look at three key companies: Novo Nordisk, PanGenomic Health, and Pfizer.
Read
Commented by Armin Schulz on June 6th, 2025 | 07:00 CEST
The US healthcare revolution: How are Bayer, PanGenomic Health, and Pfizer positioned?
The US healthcare system is undergoing unprecedented change under Secretary Robert F. Kennedy Jr. Pharmaceutical giants are groaning under drastic price controls and regulatory upheaval, while digital healthcare pioneers are sensing unprecedented opportunities. This systemic shock is tearing down old power structures and catapulting agile players to the forefront – an explosive interplay of risk and opportunity. Those who understand the new rules of the game will discover lucrative prospects amid the chaos. Today, we take a look at Bayer, PanGenomic Health, and Pfizer to see who stands to benefit.
Read
Commented by André Will-Laudien on May 20th, 2025 | 07:10 CEST
Where will the biotech winner of 2025 come from? Evotec, Bayer, BioNTech, Vidac Pharma, and Pfizer under stock review
With new announcements coming out of Washington daily, the stock market carousel is spinning faster and faster. The direction is no longer uniformly upward, but deeper corrections, such as those seen in April, offer good entry opportunities. While the DAX 40 index reached a new all-time high yesterday at 23,977 points and has already recorded 27% growth in 2025, the Nasdaq Biotech Index (NBI) has lost a full 7.2% over the past six months. We have examined several interesting sector players and identified both opportunities and risks. In short, careful selection is once again key!
Read
Commented by Armin Schulz on May 8th, 2025 | 07:05 CEST
Cancer revolution: How Bayer, Vidac Pharma, and Pfizer are shaking up the billion-dollar market
Oncology has become the scene of an unprecedented competition. Where billion-dollar markets meet life-saving innovations, a global playing field for pioneers is emerging. Forecasts show that therapy costs and market volume are growing exponentially. This poses a challenge for healthcare systems and represents a gold mine for visionaries. New technologies such as personalized cancer vaccines and targeted drugs are pushing the boundaries of what is possible. Three players are strategically positioning themselves in this dynamic environment: Bayer, Vidac Pharma, and Pfizer. Their next moves could shape not only patients' lives, but entire industries.
Read
Commented by Nico Popp on April 25th, 2025 | 07:20 CEST
US biotechs under pressure – Where opportunities now lie: BioNTech, Pfizer, and Vidac Pharma
The biotech world is in turmoil. The dispute between US President Donald Trump and the elite Harvard University is just the tip of the iceberg – thousands of researchers in the US are upset about the interference in their academic freedom. Research funding is being cut because of supposedly incorrect wording in applications. Entire degree programs are being put on hold because they do not fit into the worldview of the new US administration. The National Security Commission on Emerging Biotechnology (NSCEB) is warning of dire consequences for the US economy. Is the United States losing its status as a biotech mecca?
Read
Commented by Armin Schulz on April 17th, 2025 | 08:10 CEST
Blockbuster or takeover fever? Why Novo Nordisk, Defence Therapeutics, and Pfizer are now attracting attention
The biotech and pharmaceutical industry resembles a billion-dollar chessboard! A single move – whether a takeover or drug approval – can double share prices in a matter of hours or completely reshape entire markets. While investors are still marveling at the spectacular rally of Theratechnologies, which opened with a gap up and then soared another 45% in a single day, or analyzing the Phase-3 explosion at Corcept, the next players are already lining up for the big coup. Because in this arena, it is not just about who develops the next blockbuster but also who buys, sells, or forms strategic alliances. There are three names to have on your radar: Novo Nordisk, Defence Therapeutics, and Pfizer. Each of these companies is pursuing its own master plan.
Read
Commented by Nico Popp on April 16th, 2025 | 07:50 CEST
Takeover speculation! What is going on at Pfizer, Sanofi, and NetraMark
Developing drugs is expensive - so expensive that 22% of all Phase III studies fail due to budget constraints, as shown by scientific studies. When pharmaceutical companies discontinue a late-stage project, it also moves the stock markets. Recently, Pfizer pulled the plug on its weight loss drug, Danuglipron. The reason: a participant in the study experienced liver damage. This further backfires on Pfizer in the important market of obesity drugs, leaving it further behind Viking Therapeutics, Eli Lilly, and Novo Nordisk. To ensure that more drug trials are successful in the future, the publicly listed tech company NetraMark is relying on AI. The first pharmaceutical multinationals have already set their sights on this hidden gem.
Read